阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效观察

王晓蕊; 汪旭; 史业辉; 王忱; 佟仲生

doi:10.3969/j.issn.1000-8179.2017.15.643

阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效观察

Clinical efficacy of apatinib in treating refractory triple-negative advanced breast cancer

摘要

摘要:
目的评价阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效及不良反应。
方法回顾性分析2015年7月至2016年11月就诊于天津医科大学肿瘤医院，经病理学确诊为晚期三阴性乳腺癌，既往接受过两线以上化疗后疾病进展(progressive disease，PD)、服用阿帕替尼500 mg/d治疗的8例患者临床资料，所有患者均在接受2个周期以上治疗后评价疗效，观察PD时间、有效率、临床获益率及不良反应。
结果 8例患者共接受平均4个周期的治疗，经过中位随访时间为8 (4~11) 个月，其中部分缓解(partialremission，PR) 4例，疾病稳定(stable disease，SD) 3例，PD 1例；疾病控制率(disease control rate，DCR)为87.5%(7/8)，客观缓解率(objective response rate，ORR)为50% (4/8)，平均无进展生存期(progression free survival，PFS)为4.2个月。不良反应为手足综合征(3/8)、骨髓抑制(4/8)、高血压(2/8)、蛋白尿(3/8)、咯血(1/8)、恶心(2/8)、乏力(2/8) 等。
结论阿帕替尼在三阴性乳腺癌的治疗中可获得一定的疗效及生存获益，且安全性好，不良反应可控。

Abstract:
Objective To evaluate the effectiveness and safety of using apatinib in the treatment of refractory triple-negative advanced breast cancer.
Methods Eight cases of advanced triple-negative breast cancer patients confirmed via histopathology, who were previously treated with anthracycline, taxane, gemcitabine, capecitabine, and 500 mg/d apatinib in our hospital from July 2015 to November 2016, were retrospectively analyzed. The time of disease progress, effective rate, clinical benefits, and side effects were observed.
Results Eight patients were administrated with an average of 4 treatment cycles, and the effects were evaluated after 2 weeks. Four patients exhibited partial remission, 3 had a stable disease, and 1 had a progressive disease. The disease control rate was 87.5%, and the median progression free survival was 4.2 months. The main side effects were hand-foot syndrome (3/8), bone marrow arrest (4/8), hypertension (2/8), proteinuria (3/8), hemoptysis (1/8), nausea (2/8), and fatigue (2/8). Most of these side effects were tolerable.
Conclusion Apatinib can effectively and tolerably prolong survival time and improve the quality of life of patients with advanced triple-negative breast cancer.

HTML全文

参考文献(13)

施引文献

资源附件(0)